Carcinoma of the cervix: analysis of complications after primary external beam radiation and Ir-192 HDR brachytherapy
- PMID: 9106923
- DOI: 10.1016/s0167-8140(96)01881-6
Carcinoma of the cervix: analysis of complications after primary external beam radiation and Ir-192 HDR brachytherapy
Abstract
Background and purpose: There is still a concern that the use of HDR brachytherapy might result in an increase of late tissue damage. This restrospective study evaluates the incidence and severity of late complications in patients with carcinoma of the cervix who underwent combined external beam radiation (EBR) and Ir-192 HDR brachytherapy and attempts to identify pretreatment and treatment parameters correlating with late complications.
Material and methods: Between 1985 and 1992, 161 patients with carcinoma of the cervix (FIGO stages IB-IVB) received EBR to the pelvis (ave, max. dose 48.8 Gy) followed by 1-6 Ir-192 HDR placements (median 2). Doses to point A ranged from 8.5 to 38.7 Gy (median 17 Gy). Parameters examined included age, diabetes, obesity, history of inflammatory bowel disease or diverticulitis, prior surgery, hemoglobin level, FIGO stage, EBR dose, technique and daily dose fraction, number of HDR treatments and total dose to point A, maximum doses to bladder and rectum delivered by brachytherapy and cumulative dose to point A. Median follow-up for all patients was 37 months. Complications were rated using an in-house scoring system and according to the French-Italian Glossary (FIG).
Results: Actuarial 5-year survival was 93%, 57%, 46%, and 0% for stages IB, II, IIIB, and IV, respectively. Of 161 patients, 11% developed moderate and 3.7% severe sequelae (FIG: 2.5%, 3.7%). Since some patients experienced more than one complication, the overall incidence was 13.6% and 4.9% (FIG: 3.1%, 4.9%) with respective 5-year actuarial rates of 14% and 5% for moderate, and 2% and 8% for severe bowel and genitourinary tract complications (FIG: 3.5%, 0, and 2%, 8%). All severe bowel complications occurred within 1.5 years whereas urinary tract sequelae continued to develop throughout the follow-up period. FIGO stage was associated with a significant increase in late sequelae (P = 0.015). Analysis of the remaining pretreatment and treatment parameters failed to reveal any statistically significant correlation with moderate or severe sequelae.
Conclusion: In our series using HDR brachytherapy, complication and survival rates were comparable with other series employing either LDR or HDR procedures. Of all parameters analysed, stage of disease was the only parameter significantly correlated with complications in univariate and multivariate analysis.
Similar articles
-
High-dose-rate brachytherapy in the treatment of uterine cervix cancer. Analysis of dose effectiveness and late complications.Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1123-35. doi: 10.1016/s0360-3016(01)01533-4. Int J Radiat Oncol Biol Phys. 2001. PMID: 11483321
-
Prognostic factors in patients with carcinoma of the uterine cervix treated with external beam irradiation and IR-192 high-dose-rate brachytherapy.Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):531-40. doi: 10.1016/s0360-3016(98)00255-7. Int J Radiat Oncol Biol Phys. 1998. PMID: 9806511
-
Definitive radiotherapy based on HDR brachytherapy with iridium 192 in uterine cervix carcinoma: report on the Vienna University Hospital findings (1993-1997) compared to the preceding period in the context of ICRU 38 recommendations.Cancer Radiother. 2000 Mar-Apr;4(2):159-72. doi: 10.1016/S1278-3218(00)88900-3. Cancer Radiother. 2000. PMID: 10812362
-
Treatment results of high-dose-rate remote afterloading brachytherapy for cervical cancer and retrospective comparison of two regimens.Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1254-64. doi: 10.1016/s0360-3016(02)04525-x. Int J Radiat Oncol Biol Phys. 2003. PMID: 12654435 Review.
-
An audit of the treatment of carcinoma of the uterine cervix using external beam radiotherapy and a single line source brachytherapy technique.Br J Radiol. 1997 Dec;70(840):1259-69. doi: 10.1259/bjr.70.840.9505845. Br J Radiol. 1997. PMID: 9505845 Review.
Cited by
-
Long-term urinary adverse effects of pelvic radiotherapy.World J Urol. 2011 Feb;29(1):35-41. doi: 10.1007/s00345-010-0603-x. Epub 2010 Oct 20. World J Urol. 2011. PMID: 20959990 Free PMC article. Review.
-
Brachytherapy for cervix cancer: low-dose rate or high-dose rate brachytherapy - a meta-analysis of clinical trials.J Exp Clin Cancer Res. 2009 Apr 5;28(1):47. doi: 10.1186/1756-9966-28-47. J Exp Clin Cancer Res. 2009. PMID: 19344527 Free PMC article.
-
Assessment of long-term quality of life in patients with anal carcinomas treated by radiotherapy with or without chemotherapy.Br J Cancer. 1999 Jul;80(10):1588-94. doi: 10.1038/sj.bjc.6690567. Br J Cancer. 1999. PMID: 10408404 Free PMC article. Clinical Trial.
-
Ultrasound-assisted endocavitary HDR-Ir(192) brachytherapy for unresectable locally advanced uterine cervix carcinoma: retrospective analysis focusing the efficacy and tolerability.Clin Transl Oncol. 2013 Feb;15(2):154-9. doi: 10.1007/s12094-012-0901-4. Epub 2012 Jul 19. Clin Transl Oncol. 2013. PMID: 22855184
-
Addition of gemcitabine to standard therapy in locally advanced cervical cancer: A randomized comparative study.Indian J Med Paediatr Oncol. 2011 Jul;32(3):133-8. doi: 10.4103/0971-5851.92809. Indian J Med Paediatr Oncol. 2011. PMID: 22557778 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical